Abstract
The Phase II LCMC3 (NCT02927301) trial of neoadjuvant atezolizumab in early-stage NSCLC (primary efficacy population [patients with surgery, excluding EGFR/ALK alterations]) showed a 20% (29/143) major pathologic response (MPR, ≤10% viable tumor) rate. LCMC3 incorporated numerous biomarker analyses. We explored the impact of treatment on T-cell dynamics in the tumor and peripheral blood in association with pathologic response.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
